Cyclosam is under clinical development by QSAM Therapeutics and currently in Phase I for Metastatic Prostate Cancer. According to GlobalData, Phase I drugs for Metastatic Prostate Cancer have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cyclosam’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cyclosam is under development for the treatment of osteosarcoma, Ewing sarcoma, bone metastasis and metastatic prostate, breast, and lung cancer which is metastatic to bone. The therapeutic candidate is a radiopharmaceutical comprising samarium-153 DOTMP. It is administered through parenteral route.
For a complete picture of Cyclosam’s drug-specific PTSR and LoA scores, buy the report here.